SCHEMBL10173134

SCHEMBL10173134

CCOC(=O)c1c(OC)c(-c2ccc(Cl)nc2)nn1C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
JMJD6 Q6NYC1 1/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 2/20 0.42
DGAT1 O75907 1/20 0.41
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
SLC34A1 Q06495 5/20 0.39
POLB P06746 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
PKM P14618 1/20 0.38
MAPT P10636 1/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10140760 0.84 KMO (0.41) KDM4EALDH1A1HPGDHTT
SCHEMBL10140757 0.84 PDE10A (0.41) KDM4EALDH1A1HPGDHTTRAB9A
SCHEMBL16258975 0.82 KDM4E (0.46) JMJD6KDM4EALDH1A1HPGDHTT
SCHEMBL10172626 0.81 CYP1A2 (0.52) JMJD6ALDH1A1RAB9AMAPTLMNA
SCHEMBL16299018 0.74 KDM4E (0.47) JMJD6KDM4EALDH1A1HPGDHTT
SCHEMBL5023330 0.72 SLC34A1 (0.49) KDM4EALDH1A1HPGDRAB9ASLC34A1
SCHEMBL5023848 0.70 GABRA2 (0.48) KDM4EALDH1A1HPGDRAB9ASLC34A1
SCHEMBL29723823 0.70 DGAT1 (0.68) KDM4ERAB9ADGAT1POLBL3MBTL1
SCHEMBL71884 0.70 DGAT1 (0.68) KDM4ERAB9ADGAT1POLBL3MBTL1
SCHEMBL10140466 0.69 HPGD (0.41) ALDH1A1HPGDRAB9APKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2805939-B1 Heterocyclic compounds as factor IXA inhibitors. MERCK SHARP & DOHME (US) 2018-06-27 EP disclosed
EP-2805939-A1 Heterocyclic compounds as factor IXA inhibitors. Merck Sharp & Dohme Corp. (US) 2014-11-26 EP disclosed
US-8148363-B2 Heterocyclic compounds as factor IXA inhibitors SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065682-A1 HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS F9, F12, F8 JMJD6 1617/4885KDM4E 1387/4885ALDH1A1 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.